Gold passed $1,400 and more questions still loom over the long term impact of quantitative easing, or QE2. There is also some dissent in the Fed and oversight officials that seems to be gathering more steam. Employment data confirmed a mild improvement today, but that does not help as the data is pre-election and pre-QE2. There was also a total lack of mergers this Monday and most of the price action was in lower-priced shares.

Here were today's unofficial closing bell levels:

Dow Jones 11,406.84 -37.24 (-0.33%)
S&P 500 1,223.25 -2.60 (-0.21%)
Nasdaq 2,580.05 +1.07 (0.04%)

Top Analyst Calls

Warner Chilcott (WCRX - option chain) shares are rising today after the Food and Drug Administration approved its next generation ACTONEL product for the treatment of postmenopausal osteoporosis. WCRX will market the drug as Atelvia. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on WCRX.

WCRX opened this morning at $23.00. So far today the stock has hit a low of $22.88 and a high of $24.34. As of 12:10, WCRX is trading at $23.75 up 1.50 (6.7%). The chart for WCRX looks neutral and S&P gives WCRX a neutral 3 STARS (out of 5) hold ranking.

Analyst Upgrades

• Piper Jaffray upgraded Edwards Lifesciences (EW) to overweight from neutral and raised its target price for shares to $77 from $53 after The New England Journal of Medicine reported the company's PARTNER Trial met primary endpoints.
• UBS upgraded Endo Pharmaceuticals (ENDP) to buy from neutral and raised its price target to $36 from $25. UBS is positive on Endo's creative strategic deals and believes the switch to Opana TRF from Opana ER will be easy. Additionally, the analyst believes pipeline expectations are very low.
• BMO Capital upgraded Nvidia (NVDA) to outperform from market perform based on expectations that share loss in the core GPU business will stop, Tegra momentum and valuation. The firm raised its price target to $16 from $9.
• FirstEnergy (FE) and Allegheny Energy (AYE) were upgraded to outperform from neutral at Credit Suisse.
• Mylan (MYL) was upgraded to conviction buy from buy at Goldman. Warner
• Chilcott (WCRX) was upgraded to overweight from equal weight at Morgan Stanley.

Warner Chilcott (WCRX - option chain) shares are rising today after the company said Friday evening that it has completed a loan and debt offering needed to pay a special $8.50 per share dividend it announced last month. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on WCRX.

WCRX opened this morning at $29.00. So far today the stock has hit a low of $28.72 and a high of $29.81. As of 12:15, WCRX is trading at $29.53 up $1.41 (5.0%). The chart for WCRX looks neutral and S&P gives WCRX a neutral 3 STARS (out of 5) hold ranking.

Analyst Upgrades

• JMP Securities upgraded Boston Properties (BXP) to outperform from market perform and has an $89 price target on the stock. The firm upgraded shares based on near-term catalysts that include, the potential start of 1msf of development in Midtown, investments, and selection as 1 World Trade Center project manager.
• Baird upgraded Bucyrus (BUCY) to outperform from neutral, citing valuation and an a more favorable view of the Terex Mining acquisition. The firm has an $83 price target on the stock.
• Jefferies upgraded Warner Chilcott (WCRX) to buy from hold and has a $30 price target on the stock. The firm upgraded shares based on valuation and conservative guidance.
• AmeriCredit (ACF) was upgraded to market perform from underperform at Keefe Bruyette.
• Royal Dutch Shell (RDS.A) was upgraded to overweight from neutral at JPMorgan.
• Rio Tinto (RTP) was upgraded to outperform from market perform at Bernstein.

Analyst Upgrades

• Oppenheimer upgraded Hubbell (HUB.B) to outperform from perform to reflect the company's improving operations, margin expansion and valuation. The firm raised its target price on shares to $53 from $51.
• UBS upgraded Weingarten Realty (WRI) and Taubman Centers (TCO), Boston Properties (BXP), ProLogis (PLD) and AMB Property (AMB) to neutral from sell and SL Green Realty (SLG) to buy from neutral, citing the recent correction in the group.
• Benchmark Co. upgraded Time Warner (TWX) to buy from hold on expectations the company is positioned for steady, sustainable growth as advertising demand rebounds. The firm has a $35 price target on shares.
• Eastman Chemical (EMN) was upgraded to overweight from neutral at JPMorgan.
• Constellation Energy (CEG) was upgraded to overweight from equal weight at Barclays.
• Noble Corporation (NE) was upgraded to outperform from market perform at FBR Capital.

Analyst Upgrades

• JPMorgan upgraded Mohawk (MHK) to overweight from neutral. The firm finds shares attractive following their recent underperformance and has a positive outlook for the building products space in 2010. JPMorgan has a $53.50 price target on the stock.
• Stephens upgraded Alexander & Baldwin (ALEX) to overweight from equal weight to reflect improving volume trends and the upcoming move of the company's Transport division from Japan to Guam, which it believes will serve as a positive catalyst. Stephens raised its target price on shares to $41 from $26.
• Deutsche Bank upgraded Unum Group (UNM) to buy from hold as it believes an acceleration of growth and potential buybacks could serve as positive catalysts. The firm raised its target on shares to $26 from $25.
• News Corp. (NWS) was raised to neutral from sell at Pali Capital.
• CA Inc. (CA) was upgraded to buy from hold at Jefferies.
• Pactiv (PTV) was upgraded to buy from hold at KeyBanc.

Analyst upgrades:

• Bernstein upgraded General Electric (NYSE: GE) to Outperform from Market Perform Thursday after the close. The firm sees an improved risk/reward on the stock and raised its price target to $19 from $18.
• Bernstein also upgraded Amazon.com (NASDAQ: AMZN) to Outperform from Market Perform as it believes sales growth and margin expansion expectations are too low. The firm raised its target on shares to $160 from $125.
• Piper Jaffray upgraded CBS (NYSE: CBS) to Neutral from Underweight following the company's Q3 results and raised its target on shares to $13 from $12.
• JPMorgan upgraded Macy's (NYSE: M) to Overweight from Neutral to reflect the company's improving comps. The firm has a $23 target on the stock.
• Ansys (NASDAQ: ANSS) was upgraded to Buy from Hold at Jefferies.
• Travelers (NYSE: TRV) was upgraded to Buy from Neutral at Goldman.
• Air Methods (NASDAQ: AIRM) was upgraded to Overweight from Equal Weight at Stephens.

Analyst upgrades:

• Jefferies upgraded Warner Chilcott (NASDAQ: WCRX) to Buy from Hold. The firm views Warner Chilcott's acquisition of P&G's (NYSE: PG) pharma business as a positive given its attractive product fit and purchase price.
• ThinkEquity upgraded Google (NASDAQ: GOOG) to Buy from Source of Funds and raised its target to $550 from $400. Previously, the firm thought Google Street estimates were too high and that low single-digit growth in Q2 and Q3 would cause multiple contraction. They said their thesis played out fundamentally but they were wrong on the stock. Given Q2 has past, the analyst raised estimates above consensus and expects an in-line Q3 and for shares to outperform as the economic cycle turns.
• Bernstein upgraded Diageo (NYSE: DEO) to Outperform from Market Perform and views Diageo's valuation as attractive. The firm expects 2H09 results on August 27 to mark a bottom in weakening top-line trends.
• Costco (NASDAQ: COST) was upgraded to Market Perform from Underperform at William Blair.
• Lowe's (NYSE: LOW) was upgraded to Overweight from Equal Weight at Morgan Stanley.
• Siemens (NYSE: SI) was upgraded to Buy from Neutral at BofA/Merrill.

The dealmaking continues apace in the drug sector. Today, Warner Chilcott plc (NASDAQ: WCRX) agreed to shell out $3.1 billion for the global pharma business of Procter & Gamble (NYSE: PG). The deal is all-cash.

There are several megatrends driving the pharma deals. First, it's getting tougher to produce new drugs. And unfortunately, many pharma companies are running out on the patent protection of key money-makers. At the same time, President Obama is intent on getting some type of reform in health care.

As earnings season begins to wind down, some apparel retailers are scheduled to report quarterly results this week. Analysts polled by Thomson Reuters anticipate that Walmart Stores Inc. (NYSE: WMT), the 800-pound gorilla in the space, will report that it earned $0.77 per share in the first quarter, about the same as in the first quarter of last year. But JCPenney Co. (NYSE: JCP), Kohl's Corp. (NYSE: KSS), Nordstrom Inc. (NYSE: JWN), and Urban Outfitters Inc. (NASDAQ: URBN) are expected to report lower profits for the first quarter as consumers continued to hold off on spending. Macy's Inc. (NYSE: M) and Abercrombie & Fitch Co. (NYSE: ANF) are expected to have swung to a loss year over year.

Whole Foods Market Inc. (NASDAQ: WFMI) and Winn Dixie Stores Inc. (NASDAQ: WINN) are likewise expected to report declining earnings, while the Great Atlantic & Pacific Tea Co. (NYSE: GAP), parent of the A&P supermarket chain, is expected to have narrowed its net loss 68.9% to $0.28 per share.

Analyst upgrades:

• Goldman upgraded BT Group (NYSE: BT) to Buy from Neutral on valuation and improved earnings visibility.
  
• Soleil upgraded shares of Jo Ann Stores (NYSE: JAS) to Buy from Hold following the company's Q2 upside surprise to reflect strong fundamentals and market share gains. The firm raised Jo Ann's target to $30 from $25.
  
• Amylin Pharma (NASDAQ: AMLN) was upgraded to Buy from Neutral at Merrill Lynch.
  
• Energen (NYSE: EGN) was upgraded to Buy from Neutral at UBS.

Analyst downgrades:

• Roth Capital downgraded shares of Warner Chilcott (NASDAQ: WCRX) to Hold from Buy pending patent clarity for the company's lead drug, Loestrin 24 for birth control. The firm lowered their target to $18 from $20.
• JP Morgan cut China Mobile (NYSE: CHL) to Underweight from Overweight as they believe increased competition may limit earnings growth.
  
• Cantor downgraded shares of Cell Genesys (NASDAQ: CEGE) to Hold from Buy following the termination of the VITAL-2 Phase III clinical trial. The firm also lowered their target to $2 from $10.
• Coca-Cola (NYSE: KO) was lowered to Neutral from Outperform at Credit Suisse.
  
• Gilead Sciences (NASDAQ: GILD) was downgraded to Equal Weight from Overweight at Lehman.
  
• Cinemark (NYSE: CNK) was downgraded at BMO Capital to Market Perform from Outperform.